華大智造(688114.SH)發布靶向測序引物設計工具PrimeGen
華大智造(688114.SH)公布,旗下楊夢團隊聯合泰國朱拉隆功大學Nattiya Hirankarn教授在Nature子刊Nature Biomedical Engineering雜誌上發表線上文章,發布名為「PrimeGen」的乾濕協同多智能體系統。
該系統以大型語言模型(LLM)為中樞大腦,協調搜索、引物設計、協議腳本生成、實驗執行與質控四類智能體閉環協作,令原本需要高度依賴專家經驗的引物設計與實驗執行步驟,變成智能、快速、穩定、可追溯、可複製的標準化流程。在多場景實測中,PrimeGen在自研ATOPlex平台加持下,最多可支持955個擴增子,在保持高擴增均勻性的同時,顯著降低引物二聚體風險,預期有助推動靶向測序進入自動駕駛實驗室時代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.